Seeing Is Believing
Currently out of the existing stock ratings of Roy Buchanan, 58 are a BUY (96.67%), 2 are a HOLD (3.33%).
Analyst Roy Buchanan, currently employed at JMP, carries an average stock price target met ratio of 26.52% that have a potential upside of 23.49% achieved within 101 days.
Roy Buchanan’s has documented 119 price targets and ratings displayed on 12 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ANTX, AN2 Therapeutics at 26-Mar-2025.
Analyst best performing recommendations are on INO (INOVIO PHARMACEUTICALS).
The best stock recommendation documented was for ENTA (ENANTA PHARMACEUTICALS) at 10/4/2021. The price target of $73 was fulfilled within 18 days with a profit of $12.81 (21.28%) receiving and performance score of 11.82.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$16
$12.44 (349.44%)
$16
2 months 24 days ago
(14-Feb-2025)
0/8 (0%)
$12.35 (338.36%)
Hold
$3.9
$0.34 (9.55%)
$35
8 months 8 days ago
(30-Aug-2024)
2/2 (100%)
$0.76 (24.20%)
98
Sell
$8
$4.44 (124.72%)
$20
1 years 8 months 17 days ago
(21-Aug-2023)
4/4 (100%)
$-0.89 (-10.01%)
32
Hold
$21
$17.35 (475.34%)
$58
2 years 4 months 2 days ago
(06-Jan-2023)
1/2 (50%)
$12.74 (154.24%)
63
Sell
$47
4 years 12 days ago
(26-Apr-2021)
1/1 (100%)
$-81.95 (-63.55%)
295
Which stock is Roy Buchanan is most bullish on?
Which stock is Roy Buchanan is most reserved on?
What Year was the first public recommendation made by Roy Buchanan?